Aquestive Therapeutics (AQST) Operating Expenses (2017 - 2026)

Aquestive Therapeutics' Operating Expenses history runs 10 years deep, the most recent figure standing at $18.6 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 33.59% year-over-year to $18.6 million in Q1 2026; TTM through Mar 2026 was $106.2 million, a 11.27% increase from a year earlier, with the FY2025 full-year figure at $115.6 million, up 30.87% from the prior year.
• Operating Expenses retreated to $18.6 million in Q1 2026 per AQST's latest filing, from $41.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $41.9 million in Q4 2025 and bottomed at $15.4 million in Q3 2023.
• The 5-year median for Operating Expenses is $21.4 million (2025), against an average of $22.2 million.
• Across the five-year window, Operating Expenses surged 64.48% in 2025 and tumbled 33.59% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $21.4 million in 2022, then decreased by 20.0% to $17.1 million in 2023, then surged by 48.66% to $25.4 million in 2024, then jumped by 64.48% to $41.9 million in 2025, then tumbled by 55.44% to $18.6 million in 2026.
• Per Business Quant, the three latest AQST Operating Expenses figures stand at $18.6 million (Q1 2026), $41.9 million (Q4 2025), and $24.3 million (Q3 2025).